Copaxone Generics: FDA Approval Standards Defy Teva’s Argument On Complexity
Executive Summary
Sandoz/Momenta’s Glatopa (glatiramer) met four criteria for equivalence that ‘provide overlapping and confirmatory evidence of active ingredient sameness,’ FDA says.
You may also be interested in...
US Ruling Confirms Copaxone Is Not A Biologic
US FDA’s interpretation of ‘protein’ is reasonable and owed deference, the court concludes in tossing Teva suit which challenged Copaxone’s exclusion from list of drugs transitioned to being regulated as biologics.
Copaxone Legal Fight May Finally Be Over As Court Finds The MS Treatment Is Not A Biologic
US FDA’s interpretation of ‘protein’ is reasonable and owed deference, the court concludes in tossing Teva suit which challenged Copaxone’s exclusion from list of drugs transitioned to being regulated as biologics.
EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review
House and Senate letters ask why Mylan's autoinjector doesn't have competition, offering a preview of potential debates on renewal of the generic user fee program.